Literature DB >> 25847075

Vemurafenib/dabrafenib and trametinib.

Robert Rissmann1,2, Marleen H M Hessel2, Adam F Cohen1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25847075      PMCID： PMC4594714          DOI： 10.1111/bcp.12651

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Vemurafenib.

Authors:  Keith T Flaherty; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

3.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

4.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Authors:  Chong Sun; Liqin Wang; Sidong Huang; Guus J J E Heynen; Anirudh Prahallad; Caroline Robert; John Haanen; Christian Blank; Jelle Wesseling; Stefan M Willems; Davide Zecchin; Sebastijan Hobor; Prashanth K Bajpe; Cor Lieftink; Christina Mateus; Stephan Vagner; Wipawadee Grernrum; Ingrid Hofland; Andreas Schlicker; Lodewyk F A Wessels; Roderick L Beijersbergen; Alberto Bardelli; Federica Di Nicolantonio; Alexander M M Eggermont; Rene Bernards
Journal:  Nature       Date:  2014-03-26       Impact factor: 49.962

Review 5.  Targeting RAS-ERK signalling in cancer: promises and challenges.

Authors:  Ahmed A Samatar; Poulikos I Poulikakos
Journal:  Nat Rev Drug Discov       Date:  2014-12       Impact factor: 84.694
  5 in total
  7 in total

1.  Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer.

Authors:  Shini Liu; Qiong Zou; Jie-Ping Chen; Xiaosai Yao; Peiyong Guan; Weiting Liang; Peng Deng; Xiaowei Lai; Jiaxin Yin; Jinghong Chen; Rui Chen; Zhaoliang Yu; Rong Xiao; Yichen Sun; Jing Han Hong; Hui Liu; Huaiwu Lu; Jianfeng Chen; Jin-Xin Bei; Joanna Koh; Jason Yongsheng Chan; Baohua Wang; Tiebang Kang; Qiang Yu; Bin-Tean Teh; Jihong Liu; Ying Xiong; Jing Tan
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

2.  Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAFV600E mutation treated with dabrafenib-trametinib: a case report.

Authors:  M C Martín-Soberón; S Ruiz; G De Velasco; R Yarza; A Carretero; D Castellano; J M Sepúlveda-Sánchez
Journal:  J Med Case Rep       Date:  2021-03-02

3.  Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.

Authors:  Niranjan Awasthi; Sheena Monahan; Alexis Stefaniak; Margaret A Schwarz; Roderich E Schwarz
Journal:  Oncotarget       Date:  2017-12-25

Review 4.  Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.

Authors:  Arjun Khunger; Monica Khunger; Vamsidhar Velcheti
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

5.  Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival.

Authors:  Jennifer Ferguson; Daniel J Wilcock; Sophie McEntegart; Andrew P Badrock; Mitch Levesque; Reinhard Dummer; Claudia Wellbrock; Michael P Smith
Journal:  Pigment Cell Melanoma Res       Date:  2019-08-08       Impact factor: 4.693

Review 6.  The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer.

Authors:  Longyao Zhang; Linpeng Zheng; Qiao Yang; Jianguo Sun
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

Review 7.  Trametinib: a MEK inhibitor for management of metastatic melanoma.

Authors:  Iwona Lugowska; Hanna Koseła-Paterczyk; Katarzyna Kozak; Piotr Rutkowski
Journal:  Onco Targets Ther       Date:  2015-08-25       Impact factor: 4.147
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.